Hoth Therapeutics和Silo Pharma成立战略合资公司，开发和商业化基于美国退伍军人事务部独家许可的技术的肥胖症和代谢性疾病治疗

*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market

Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease

NEW YORK, June 25, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) and Silo Pharma, Inc. (NASDAQ:SILO) today announced the formation of a strategic joint venture to develop and commercialize a first-in-class treatment for obesity and metabolic disease based on technology exclusively licensed from the U.S. Department of Veterans Affairs (VA).

The novel therapeutic platform centers on Glial Cell Line-Derived Neurotrophic Factor (GDNF), a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models. The platform is protected under U.S. Patent No. 10,052,362 and targets multiple high-burden conditions including non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and central obesity.

Deal Highlights:

• Exclusive U.S. License from the U.S. Department of Veterans Affairs covering all fields of use
• 50/50 Joint Venture structure with equal equity and governance participation 
• Lead Indication: Obesity and NAFLD